Glenmark Pharmaceuticals announces successful closure of $200 million Bond

26 Jul 2016 Evaluate

Glenmark Pharmaceuticals has successfully closed the pricing of its debut $200 million 5-year non-call 3 year senior unsecured notes offering at 4.5% per annum, due 2021 (the 2016 Notes). The notes issuance follows a series of fixed income investor meetings in Asia and Europe, and was priced following strong demand aggregating $1.7 billion from a wide spectrum of institutional investors across Asia and Europe.

The bonds were oversubscribed 8 times and the notes have been rated BB and BB by S&P and Fitch respectively. The proceeds from the issuance and sale of the Notes will be used for investment in Glenmark’s wholly owned subsidiaries abroad, and will subsequently be applied to repay existing debt at the subsidiary level.

Citi and HSBC acted as Joint Global Coordinators and ANZ, Barclays and DB5 Bank acted as Joint Bookrunners and Joint Lead Managers to the offering.

Glenmark Pharma Share Price

2000.60 -10.90 (-0.54%)
16-Jan-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1669.20
Dr. Reddys Lab 1175.55
Cipla 1397.95
Zydus Lifesciences 867.80
Lupin 2176.25
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×